Rytelo FDA Approval History
Last updated by Carmen Pope, BPharm on June 10, 2024.
FDA Approved: Yes (First approved June 6, 2024)
Brand name: Rytelo
Generic name: imetelstat
Dosage form: for Injection
Company: Geron Corporation
Treatment for: Myelodysplastic Syndrome
Rytelo (imetelstat) is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
- Myelodysplastic syndromes are a group of disorders caused by the malfunctioning of stem cells in the bone marrow. Insufficient red blood cell production causes anemia that can require regular blood transfusions.
- Rytelo works to treat transfusion-dependent anemia in MDS patients by binding to and inhibiting the activity of the enzyme telomerase to selectively kill the malignant stem and progenitor cells in the bone marrow.
Development timeline for Rytelo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
